# Rivaroxaban in Idiopathic Membranous Nephropathy

> **NCT07404436** · PHASE4 · RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 134 (estimated)

## Conditions studied

- Idiopathic Membranous Nephropathy

## Interventions

- **DRUG:** Rivaroxaban 10 MG
- **DRUG:** Warfarin Sodium

## Key facts

- **NCT ID:** NCT07404436
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07404436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07404436, "Rivaroxaban in Idiopathic Membranous Nephropathy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07404436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*